White House Ties Federal Research Funds to Certified DNA Suppliers Under New Synthesis Screening Policy
NSTM-6, issued November 5, draws tempered praise from biosecurity experts but leaves open questions about AI-designed sequences that don't match known threat lists.
The White House issued a government-wide mandatory screening policy for synthetic DNA on November 5, replacing a voluntary framework that biosecurity researchers had spent years calling insufficient. The document, known as NSTM-6, makes compliance a condition of receiving federal life sciences funding, a funding lever that prior frameworks lacked entirely.
The policy is straightforward in its mechanism. <cite index="21-6">NASS requires all recipients of federal life sciences funding to procure synthetic nucleic acids and benchtop synthesis equipment exclusively from certified suppliers that verify the legitimacy of customers and sequences ordered.</cite> <cite index="22-5">Federally funded researchers must buy synthetic nucleic acids and benchtop synthesizers only from certified providers that screen orders of 50 or more nucleotides using NIST-verified tools, verify customers, report flagged orders, and keep records for eight years, with full implementation phased in over roughly a year.</cite>
<cite index="20-2">On November 5, 2026, the White House issued NSTM-6, a memorandum from National Security Advisor Marco Rubio and OSTP Director Michael J. Kratsios that attaches the National Policy for Nucleic Acid Synthesis Screening.</cite> <cite index="20-4">The memorandum states that the Policy implements Executive Order 14292, replaces the 2024 Framework for Nucleic Acid Synthesis Screening, and on full implementation also replaces the 2023 HHS Screening Framework Guidance.</cite>
The timing is worth noting. <cite index="24-7,24-8">An executive order addressing dangerous gain-of-function research signed by President Donald Trump on May 5, 2025, required the government to produce the screening policy in 90 days. Roughly 460 days after that specified deadline, the White House published the policy.</cite> That gap isn't trivial. The dual-use risk environment didn't pause while the policy was drafted.
Biosecurity experts have called the new rules a step forward, but their praise carries caveats. <cite index="26-10">Researchers have warned that list-based screening may miss AI-designed sequences that do not closely match known threats.</cite> That's not a minor gap. <cite index="10-2,10-3">A perspective published November 9 in Nature proposes that dual-use research of concern policies should reflect emerging risks from recent technological innovations, including artificial intelligence. In virology and biosecurity fields, gain-of-function mutations can fall under DURC considerations, in which proposed experiments could potentially cause harm through methodologies, materials, or results if misused.</cite> <cite index="10-8">Current biosecurity and DURC policies have blind spots and might be too narrow in scope and practice.</cite>
To address part of that gap, <cite index="25-2">the policy also directs NIST to develop risk-based rather than list-based oversight and AI-assisted screening methods.</cite> That's a sensible direction, but it's a directive to build a tool, not the tool itself. How quickly NIST can operationalize risk-based screening, and whether the certification process for suppliers keeps pace with the AI-accelerated biology research it's meant to cover, are open questions the policy text doesn't resolve.
The benchtop synthesizer provision deserves separate attention. <cite index="26-9">Benchtop synthesizers, desktop machines that let a lab make DNA in-house, will need a valid authorization from a verified screening system before they can run.</cite> These devices are the chokepoint that prior policy essentially ignored. If a researcher or a bad actor can synthesize sequences on-premises without going through a commercial supplier, supplier screening is only partial coverage. Putting benchtop equipment inside the same compliance boundary as commercial orders closes a real structural hole.
What remains unaddressed is the international dimension. NSTM-6 applies to federally funded U.S. researchers. It doesn't govern foreign suppliers or foreign-funded labs, and <cite index="16-7">an assessment found that of twenty-seven countries possessing or developing high-containment labs, only twelve scored high on biosecurity and only one, Canada, scored high on dual-use research governance.</cite> A U.S. policy that tightens one node in the synthetic biology supply chain is worth having. It's not a closed loop.
The OSTP and NSC framed the policy as building "a dynamic biosecurity defense centered on strong controls over the materials that enable synthetic biology misuse," according to the NSTM-6 memorandum reviewed by Science and confirmed through the White House document. The confidence level on that claim is moderate at best until the NIST-verified screening infrastructure is actually built and the supplier certification process proves it can keep up.
Sources cited:
- White House NSTM-6 (PDF) (https://www.whitehouse.gov/wp-content/uploads/2026/11/NSTM-6-NASS-Policy.pdf)
- Science (https://www.science.org/content/article/deter-bioterrorism-u-s-imposes-new-rules-ordering-synthetic-dna)
- CASRAI (NSTM-6 analysis) (https://casrai.org/news/white-house-nucleic-acid-synthesis-screening-policy-2026)
- Congressional Research Service, IF13269 (https://www.congress.gov/crs-product/IF13269)
- Nature (dual-use virology and AI) (https://www.nature.com/articles/s41564-026-02522-0)
- Atlantic Council (https://www.atlanticcouncil.org/dispatches/its-not-just-misuse-ai-enabled-biological-research-also-runs-the-risk-of-accidents/)
- Medical Daily (https://www.medicaldaily.com/white-house-federal-dna-screening-policy-481133)
This release was originally distributed via ETL Newswire. Visit White House NSTM-6 (PDF) for the full story, related releases, and contact information.
Visit White House NSTM-6 (PDF) →